Professor Yu Wang obtained her PhD in Biomedicine and Proteomics from the University of Auckland in 2003, and then worked as a Research Fellow at Maurice Wilkins Centre for Molecular Biodiscovery, in charge of the Proteomics Biodiscovery Center. During this period, she characterized the important posttranslational modifications of adiponectin, an anti-diabetic, anti-inflammatory, anti-atherosclotic, anti-cancer and hepatoprotective hormone. Her work on adiponectin has been cited over 8000 times.

Professor Wang joined HKU as a Research Assistant Professor in 2004, and helped with the establishment of various Proteomic facilities in the Genome Research Center, currently the Centre for PanorOmic Sciences. During this period, she carried out independent research on Biomarker discoveries using “Omics” approaches and identified a series of novel biomarkers, such as lipocalin-2, fatty acid-binding protein 4, angiopoietin-like 4, FGF21 and SIRT1, which represent promising “druggale” targets in ageing-related cardiovascular, metabolic and cancer diseases.

In 2008, Prof Wang joined the Department of Pharmacology, currently the Department of Pharmacology and Pharmacy, HKU. She was promoted to Associate Professor and Professor in 2012 and 2018, respectively. Her current research is focusing on a number of “druggale” targets in ageing-related cardiovascular, metabolic and cancer diseases. Her group is performing molecular, cellular, pharmacological studies in both animal and human subjects to explore different approaches of intervention, largely based on the druggable biomolecules adiponectin, lipocalin-2 and SIRT1. Prof Wang has published over 200 journal articles/book chapters/invited reviews/commentaries, and is among the top 1% highly cited scientist with an H-index of 70.